Insider Selling: Artivion (NYSE:AORT) Insider Sells 4,573 Shares of Stock

Artivion, Inc. (NYSE:AORT) insider John Davis sold 4,573 shares of the company’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $37.78, for a total transaction of $172,767.94. Following the completion of the transaction, the insider owned 230,794 shares of the company’s stock, valued at approximately $8,719,397.32. This trade represents a 1.94% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Artivion Price Performance

AORT traded down $0.21 during trading on Wednesday, reaching $38.41. The stock had a trading volume of 460,494 shares, compared to its average volume of 509,518. The stock has a 50 day moving average of $41.42 and a two-hundred day moving average of $42.92. The firm has a market capitalization of $1.84 billion, a price-to-earnings ratio of 61.30 and a beta of 1.60. Artivion, Inc. has a 1-year low of $21.97 and a 1-year high of $48.25. The company has a quick ratio of 2.62, a current ratio of 3.53 and a debt-to-equity ratio of 0.49.

Artivion (NYSE:AORT) last released its earnings results on Thursday, February 12th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of $0.14 by $0.03. The business had revenue of $118.30 million during the quarter, compared to analyst estimates of $116.42 million. Artivion had a net margin of 2.21% and a return on equity of 7.43%. The firm’s quarterly revenue was up 19.2% on a year-over-year basis. As a group, equities analysts anticipate that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Wall Street Zen lowered Artivion from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Needham & Company LLC restated a “buy” rating and set a $58.00 price target on shares of Artivion in a report on Monday, February 2nd. Weiss Ratings raised shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, February 20th. Oppenheimer reaffirmed an “outperform” rating and issued a $50.00 price target on shares of Artivion in a research note on Friday, November 7th. Finally, Citizens Jmp lifted their price objective on Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a research report on Friday, November 7th. Six research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, Artivion presently has a consensus rating of “Moderate Buy” and an average price target of $48.97.

Institutional Trading of Artivion

Large investors have recently made changes to their positions in the stock. Royal Bank of Canada increased its holdings in shares of Artivion by 107.0% during the 1st quarter. Royal Bank of Canada now owns 38,707 shares of the company’s stock valued at $952,000 after acquiring an additional 20,010 shares during the last quarter. AQR Capital Management LLC grew its holdings in Artivion by 8.8% during the first quarter. AQR Capital Management LLC now owns 35,053 shares of the company’s stock valued at $862,000 after purchasing an additional 2,823 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Artivion by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,591 shares of the company’s stock valued at $580,000 after purchasing an additional 1,032 shares during the period. Envestnet Asset Management Inc. raised its holdings in Artivion by 364.4% in the 2nd quarter. Envestnet Asset Management Inc. now owns 52,871 shares of the company’s stock worth $1,644,000 after acquiring an additional 41,487 shares during the period. Finally, Atria Investments Inc bought a new stake in Artivion during the second quarter valued at about $244,000. Institutional investors own 86.37% of the company’s stock.

Artivion News Summary

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Analysts remain constructive — consensus rating is “Moderate Buy” with several buy/outperform notes and mid‑to‑high price targets that support investor demand. Artivion Receives Consensus Rating
• Positive Sentiment: Management will present at the Oppenheimer Healthcare MedTech & Services Conference (virtual fireside chat), giving the company an opportunity to update investors on growth drivers, product progress and commercial milestones. Conferences can re‑ignite buying interest if guidance or pipeline commentary is favorable. Artivion to Participate in Oppenheimer Conference
• Positive Sentiment: Large institutional investors have been adding exposure (Invesco and others increased stakes), which can provide a steady bid and signals confidence from professional investors. MarketBeat – Artivion Institutional Activity
• Neutral Sentiment: Recent quarterly results beat revenue and EPS estimates and showed strong year‑over‑year revenue growth; that supports the bull case but may already be reflected in the share price and analyst upgrades. MarketBeat – Artivion Earnings Summary
• Negative Sentiment: Multiple senior insiders sold stock over March 2–4 (including the CEO and several EVPs/SVPs). A concentrated block of insider sales often weighs on sentiment even when executives retain large holdings — markets can interpret it as opportunistic liquidity or as a signal of limited near‑term confidence. Insider Trades Alert

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.